Han Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Han Wu has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Fuxiang Zhou
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University
2 shared publications - Lei Yang
Hubei Cancer Clinical Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, China
2 shared publications - Binlei Liu
National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Hubei University of Technology, Wuhan, China
1 shared publication - Bo Zhai
Mini-Invasive Interventional Therapy Center, Shanghai East Hospital, Tongji University, Shanghai, China
1 shared publication - Cai-Yang Chen
Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
1 shared publication - Dan Tang
Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 11 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1986810
Oncolytic viruses in combination cancer therapy: clinical lessons, biomarker-guided strategies, and future treatment directions
Oncolytic viruses (OVs) preferentially infect and replicate within tumors, induce immunogenic cell death, and remodel immune-poor microenvironments to support T-cell infiltration. These features provide a rationale for combining OVs with immune checkpoint blockade, adoptive cellular therapies, bispecific T-cell engagers, cancer vaccines, and innate immune agonists, and for engineering viruses to express immunostimulatory cytokines. Clinical outcomes, however, have been inconsistent. In MASTERKEY-265, adding intratumoral talimogene laherparepvec to pembrolizumab did not significantly improve progression-free or overall survival in advanced melanoma, despite a 62% objective response rate in the preceding 21-patient phase Ib cohort and evidence of increased intratumoral CD8+ T cells and PD-L1 expression. In contrast, single-arm clinical data for RP1 plus nivolumab in anti-PD-1-refractory melanoma showed objective responses, including durable responses in a subset; the U.S. Food and Drug Administration granted accelerated approval for the regimen, but randomized confirmation remains required. Together with the failure of PHOCUS, these findings indicate that benefit is determined by viral platform, tumor immune state, disease and prior-treatment setting, delivery feasibility, and resistance biology rather than immune activation alone. We critically synthesize positive and negative evidence across checkpoint and non-checkpoint strategies and distinguish biomarkers derived from OV studies from those extrapolated from checkpoint-inhibitor trials. Candidate biomarkers and pharmacodynamic readouts are organized into a three-tier research framework covering pretreatment characterization, platform–partner hypotheses, and on-treatment monitoring; their utility for selecting OV-based combinations still requires validation. We further examine delivery barriers, antiviral immunity, tumor heterogeneity and resistance, next-generation vector engineering, and computational approaches to molecularly guided patient selection. Prospective validation in biomarker-stratified, adaptive trials is needed to improve patient selection, match viral platforms with rational partners, and translate biological activity into durable clinical benefit.
- 11 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1986810
Open AccessOncolytic viruses in combination cancer therapy: clinical lessons, biomarker-guided strategies, and future treatment directions
Oncolytic viruses (OVs) preferentially infect and replicate within tumors, induce immunogenic cell death, and remodel immune-poor microenvironments to support T-cell infiltration. These features provide a rationale for combining OVs with immune checkpoint blockade, adoptive cellular therapies, bispecific T-cell engagers, cancer vaccines, and innate immune agonists, and for engineering viruses to express immunostimulatory cytokines. Clinical outcomes, however, have been inconsistent. In MASTERKEY-265, adding intratumoral talimogene laherparepvec to pembrolizumab did not significantly improve progression-free or overall survival in advanced melanoma, despite a 62% objective response rate in the preceding 21-patient phase Ib cohort and evidence of increased intratumoral CD8+ T cells and PD-L1 expression. In contrast, single-arm clinical data for RP1 plus nivolumab in anti-PD-1-refractory melanoma showed objective responses, including durable responses in a subset; the U.S. Food and Drug Administration granted accelerated approval for the regimen, but randomized confirmation remains required. Together with the failure of PHOCUS, these findings indicate that benefit is determined by viral platform, tumor immune state, disease and prior-treatment setting, delivery feasibility, and resistance biology rather than immune activation alone. We critically synthesize positive and negative evidence across checkpoint and non-checkpoint strategies and distinguish biomarkers derived from OV studies from those extrapolated from checkpoint-inhibitor trials. Candidate biomarkers and pharmacodynamic readouts are organized into a three-tier research framework covering pretreatment characterization, platform–partner hypotheses, and on-treatment monitoring; their utility for selecting OV-based combinations still requires validation. We further examine delivery barriers, antiviral immunity, tumor heterogeneity and resistance, next-generation vector engineering, and computational approaches to molecularly guided patient selection. Prospective validation in biomarker-stratified, adaptive trials is needed to improve patient selection, match viral platforms with rational partners, and translate biological activity into durable clinical benefit.
- Open Access
- 3 April 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Integrated single-cell and bulk RNA sequencing analysis identifies a pyroptosis related prognostic model for predicting prognosis and therapeutic response in intrahepatic cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (iCCA) is the second most common aggressive liver malignancy. The heterogeneous nature of iCCA poses a serious challenge for prognostic prediction and individualized therapy. Pyroptosis, a novel programmed cell death, has recently been implicated in the development and treatment of human cancers. However, its clinical significance in iCCA is unclear. Single-cell sequencing data was analyzed to uncover the transcriptomic heterogeneity, intercellular crosstalk, and pyroptosis levels of iCCA cells. A pyroptosis-related prognostic model was constructed, and the prognostic efficiency was validated in an external cohort. Five iCCA cell clusters were identified. Cluster1 with the highest pyroptosis score showed an intimate cell-cell communication with cluster3 that represented acute inflammatory response activity. Pyroptosis genes along pseudotime showed distinguishable distribution among three subtypes in cluster1. Risk score was proved as an independent prognostic factor. High-risk patients demonstrated high TMB, MSI-H phenotype, and poorer survival. Tumor immune infiltration characteristics and chemotherapeutics response demonstrated difference in the two risk groups. Targeted drug tanespimycin was positively correlated with hub gene BNIP3, and refametinib and crizotinib showed negative association with JUN. The pyroptosis-related model demonstrated potential in predicting prognosis and individualized therapy strategies.
- 3 April 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessIntegrated single-cell and bulk RNA sequencing analysis identifies a pyroptosis related prognostic model for predicting prognosis and therapeutic response in intrahepatic cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (iCCA) is the second most common aggressive liver malignancy. The heterogeneous nature of iCCA poses a serious challenge for prognostic prediction and individualized therapy. Pyroptosis, a novel programmed cell death, has recently been implicated in the development and treatment of human cancers. However, its clinical significance in iCCA is unclear. Single-cell sequencing data was analyzed to uncover the transcriptomic heterogeneity, intercellular crosstalk, and pyroptosis levels of iCCA cells. A pyroptosis-related prognostic model was constructed, and the prognostic efficiency was validated in an external cohort. Five iCCA cell clusters were identified. Cluster1 with the highest pyroptosis score showed an intimate cell-cell communication with cluster3 that represented acute inflammatory response activity. Pyroptosis genes along pseudotime showed distinguishable distribution among three subtypes in cluster1. Risk score was proved as an independent prognostic factor. High-risk patients demonstrated high TMB, MSI-H phenotype, and poorer survival. Tumor immune infiltration characteristics and chemotherapeutics response demonstrated difference in the two risk groups. Targeted drug tanespimycin was positively correlated with hub gene BNIP3, and refametinib and crizotinib showed negative association with JUN. The pyroptosis-related model demonstrated potential in predicting prognosis and individualized therapy strategies.
- Open Access
- 29 January 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (2)
Hepatocyte-derived liver progenitor-like cells attenuate liver cirrhosis via induction of apoptosis in hepatic stellate cells
Background: Cell therapy demonstrates promising potential as a substitute therapeutic approach for liver cirrhosis. We have developed a strategy to effectively expand murine and human hepatocyte-derived liver progenitor-like cells (HepLPCs) in vitro. The primary objective of the present study was to apply HepLPCs to the treatment of liver cirrhosis and to elucidate the underlying mechanisms responsible for their therapeutic efficacy. Methods: The effects of allogeneic or xenogeneic HepLPC transplantation were investigated in rat model of liver cirrhosis. Liver tissues were collected and subjected to immunostaining to assess changes in histology. In vitro experiments used HSCs to explore the antifibrotic properties of HepLPC-secretomes and their underlying molecular mechanisms. Additionally, proteomic analysis was conducted to characterize the protein composition of HepLPC-secretomes. Results: Transplantation of HepLPCs resulted in decreased active fibrogenesis and net fibrosis in cirrhosis models. Apoptosis of HSCs was observed in vivo after HepLPC treatment. HepLPC-secretomes exhibited potent inhibition of TGF-β1-induced HSC activation and promoted apoptosis through signal transducer and activator of transcription (STAT)1-mediated pathways in vitro. Furthermore, synergistic effects between amphiregulin and FGF19 within HepLPC-secretomes were identified, contributing to HSC apoptosis and exerting antifibrotic effects via activation of the janus kinase-STAT1 pathway. Conclusions: HepLPCs have the potential to ameliorate liver cirrhosis by inducing STAT1-dependent apoptosis in HSCs. Amphiregulin and FGF19 are key factors responsible for STAT1 activation, representing promising novel therapeutic targets for the treatment of liver cirrhosis.
- 29 January 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (2)
Open AccessHepatocyte-derived liver progenitor-like cells attenuate liver cirrhosis via induction of apoptosis in hepatic stellate cells
Background: Cell therapy demonstrates promising potential as a substitute therapeutic approach for liver cirrhosis. We have developed a strategy to effectively expand murine and human hepatocyte-derived liver progenitor-like cells (HepLPCs) in vitro. The primary objective of the present study was to apply HepLPCs to the treatment of liver cirrhosis and to elucidate the underlying mechanisms responsible for their therapeutic efficacy. Methods: The effects of allogeneic or xenogeneic HepLPC transplantation were investigated in rat model of liver cirrhosis. Liver tissues were collected and subjected to immunostaining to assess changes in histology. In vitro experiments used HSCs to explore the antifibrotic properties of HepLPC-secretomes and their underlying molecular mechanisms. Additionally, proteomic analysis was conducted to characterize the protein composition of HepLPC-secretomes. Results: Transplantation of HepLPCs resulted in decreased active fibrogenesis and net fibrosis in cirrhosis models. Apoptosis of HSCs was observed in vivo after HepLPC treatment. HepLPC-secretomes exhibited potent inhibition of TGF-β1-induced HSC activation and promoted apoptosis through signal transducer and activator of transcription (STAT)1-mediated pathways in vitro. Furthermore, synergistic effects between amphiregulin and FGF19 within HepLPC-secretomes were identified, contributing to HSC apoptosis and exerting antifibrotic effects via activation of the janus kinase-STAT1 pathway. Conclusions: HepLPCs have the potential to ameliorate liver cirrhosis by inducing STAT1-dependent apoptosis in HSCs. Amphiregulin and FGF19 are key factors responsible for STAT1 activation, representing promising novel therapeutic targets for the treatment of liver cirrhosis.
- Open Access
- 14 June 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (6) , 693
Exploring the Molecular Mechanism of Comorbidity of Type 2 Diabetes Mellitus and Colorectal Cancer: Insights from Bulk Omics and Single-Cell Sequencing Validation
The relationship between type 2 diabetes mellitus (T2DM) and colorectal cancer (CRC) has long been extensively recognized, but their crosstalk mechanisms based on gene regulation remain elusive. In our study, for the first time, bulk RNA-seq and single-cell RNA-seq data were used to explore the shared molecular mechanisms between T2DM and CRC. Moreover, Connectivity Map and molecular docking were employed to determine potential drugs targeting the candidate targets. Eight genes (EVPL, TACSTD2, SOX4, ETV4, LY6E, MLXIPL, ENTPD3, UGP2) were identified as characteristic comorbidity genes for T2DM and CRC, with EVPL and ENTPD3 further identified as core comorbidity genes. Our results demonstrated that upregulation of EVPL and downregulation of ENTPD3 were intrinsic molecular features throughout T2DM and CRC and were significantly associated with immune responses, immune processes, and abnormal immune landscapes in both diseases. Single-cell analysis highlighted a cancer-associated fibroblast (CAF) subset that specifically expressed ENTPD3 in CRC, which exhibited high heterogeneity and unique tumor-suppressive features that were completely different from classical cancer-promoting CAFs. Furthermore, ENTPD3+ CAFs could notably predict immunotherapy response in CRC, holding promise to be an immunotherapy biomarker at the single-cell level. Finally, we identified that droperidol may be a novel drug simultaneously targeting EVPL and ENTPD3. In conclusion, previous studies have often focused solely on metabolic alterations common to T2DM and CRC. Our study establishes EVPL and ENTPD3 as characteristic molecules and immune biomarkers of comorbidity in T2DM and CRC patients, and emphasizes the importance of considering immunological mechanisms in the co-development of T2DM and CRC.
- 14 June 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (6) , 693
Open AccessExploring the Molecular Mechanism of Comorbidity of Type 2 Diabetes Mellitus and Colorectal Cancer: Insights from Bulk Omics and Single-Cell Sequencing Validation
The relationship between type 2 diabetes mellitus (T2DM) and colorectal cancer (CRC) has long been extensively recognized, but their crosstalk mechanisms based on gene regulation remain elusive. In our study, for the first time, bulk RNA-seq and single-cell RNA-seq data were used to explore the shared molecular mechanisms between T2DM and CRC. Moreover, Connectivity Map and molecular docking were employed to determine potential drugs targeting the candidate targets. Eight genes (EVPL, TACSTD2, SOX4, ETV4, LY6E, MLXIPL, ENTPD3, UGP2) were identified as characteristic comorbidity genes for T2DM and CRC, with EVPL and ENTPD3 further identified as core comorbidity genes. Our results demonstrated that upregulation of EVPL and downregulation of ENTPD3 were intrinsic molecular features throughout T2DM and CRC and were significantly associated with immune responses, immune processes, and abnormal immune landscapes in both diseases. Single-cell analysis highlighted a cancer-associated fibroblast (CAF) subset that specifically expressed ENTPD3 in CRC, which exhibited high heterogeneity and unique tumor-suppressive features that were completely different from classical cancer-promoting CAFs. Furthermore, ENTPD3+ CAFs could notably predict immunotherapy response in CRC, holding promise to be an immunotherapy biomarker at the single-cell level. Finally, we identified that droperidol may be a novel drug simultaneously targeting EVPL and ENTPD3. In conclusion, previous studies have often focused solely on metabolic alterations common to T2DM and CRC. Our study establishes EVPL and ENTPD3 as characteristic molecules and immune biomarkers of comorbidity in T2DM and CRC patients, and emphasizes the importance of considering immunological mechanisms in the co-development of T2DM and CRC.